BTX-A51 is the first inhibitor targeting CK1α to enter clinical trials (NCT04243785) for the treatment of acute myeloid leukemia and myelodysplastic syndrome (11, 17, 18). The gene discussed is CSNK1A1; the disease is acute myeloid leukemia.